Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The robotic surgery program has continually pushed the boundaries of medical technology
Majority of organizations are looking to increase investments in public and hybrid cloud
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Subscribe To Our Newsletter & Stay Updated
